Four pharmaceutical companies had generic extended-release Adderall on backorder in August at a time of unprecedented demand for the attention-deficit/hyperactivity disorder drug.
Together, the companies sell just over ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
